The demand for anti-diabetes drugs in ASEAN has been increasing in recent years, driven by a growing prevalence of diabetes in the region.
Customer preferences: Customers in ASEAN tend to prefer affordable and accessible anti-diabetes drugs that have been proven effective in managing their condition. Many patients in the region have limited access to healthcare, which means that they may not be able to afford expensive medication or travel long distances to receive treatment. As a result, there is a high demand for affordable generic drugs that are widely available in local pharmacies.
Trends in the market: Indonesia is the largest market for anti-diabetes drugs in ASEAN, with a significant portion of the population suffering from diabetes. The market in Indonesia is dominated by generic drugs, which account for the majority of sales. In contrast, the market in Singapore is more focused on branded drugs, with a higher proportion of sales coming from newer, more expensive medications. In Malaysia, there has been a growing trend towards using combination therapies, which involve combining multiple drugs to achieve better glycemic control.
Local special circumstances: One of the biggest challenges facing the anti-diabetes drugs market in ASEAN is the lack of awareness and education around diabetes. Many people in the region do not understand the risks associated with the disease or how to manage it effectively. This has led to a high prevalence of undiagnosed cases and poor disease management. To address this, there have been efforts to increase public awareness and improve access to healthcare services.
Underlying macroeconomic factors: The growing prevalence of diabetes in ASEAN is largely driven by changing lifestyles and a shift towards more sedentary and unhealthy behaviors. Rapid urbanization and economic development have led to changes in diet and physical activity levels, which have contributed to the rise in diabetes cases. Additionally, an aging population and increasing rates of obesity are also contributing to the growing burden of diabetes in the region. As a result, there is a need for more effective and accessible anti-diabetes drugs to manage the disease and reduce its impact on public health.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
